ENMD-0995 (S 3-APG), a novel thalidomide analogue, has promising clinical activity for patients with relapsed refractory multiple myeloma. Preliminary results of a phase I clinical trial.

被引：0
|
作者：
Lacy, MQ
Dispenzieri, A
Gertz, MA
Wilzig, TE
Greipp, PR
Fonseca, R
Lust, JA
Kumar, S
Zeldenrust, S
Kyle, RA
Snow, D
Hayman, SR
Sidor, CF
Treston, AM
Zeldis, JB
Rajkumar, SV
机构：
[1] Celgene Corp, Warren, NJ USA
[2] Entremed Inc, Rockford, IL USA
[3] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1654
引用
收藏
页码：453A / 453A
页数：1
相关论文
共 50 条
  • [31] Preliminary safety and efficacy results from an international phase 3b study for expanded access to bortezomib in 624 patients with relapsed and/or refractory multiple myeloma.
    Mikhael, Joseph R.
    Belch, Andrew
    Prince, Miles
    Lucio, Maria Nambo
    Maiolino, Angelo
    Corso, Alessandro
    Petrucci, Maria Teresa
    Mieczyslaw, Komarnicki
    Stewart, A. Keith
    BLOOD, 2006, 108 (11) : 1007A - 1007A
  • [32] High Response Rates with the Combination of Bortezomib, Dexamethasone and the Pan-Histone Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma in a Phase I/II Clinical Trial.
    Harrison, Simon James
    Quach, Hang
    Yuen, Kally
    Strayer, Andrew
    Copeman, Michael C.
    Peinert, S.
    Bishton, M.
    Wolf, M.
    Januszewicz, H.
    Kencaly, Mk
    Herbert, K.
    Westerman, David
    Carney, D.
    Seymour, J. F.
    Johnstone, R. W.
    Ritchie, David
    Prince, Miles
    BLOOD, 2008, 112 (11) : 1267 - 1267
  • [33] A multicenter phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: Preliminary results. Multiple myeloma research consortium (MMRC) trial
    Jakubowiak, A.
    Richardson, P.
    Zimmerman, T.
    Alsina, M.
    Lonial, S.
    Kendall, T.
    Hideshima, T.
    Sportelli, P.
    Birch, R.
    Henderson, I. C.
    Giusti, K.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 154 - 155
  • [34] A phase II multiple dose clinical trial of historic deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma: Preliminary results
    Galli, Monica
    Salmoiraghi, Silvia
    Golay, Josee
    Gozzini, Antonella
    Bosi, Alberto
    Crippa, Claudia
    Rossi, Giuseppe
    Pescosta, Norbert
    Cortelazzo, Sergio
    Sechi, Alessandra
    Oldoni, Tiziano
    Rambaldi, Alessandro
    BLOOD, 2007, 110 (11) : 356A - 356A
  • [35] Bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma: Final results of a phase I/II clinical trial
    Popat, Rakesh
    Williams, Catherine
    Cook, Mark
    Craddock, Charles
    Basu, Supratik
    Singer, Charles
    Odeh, Liz
    Foot, Nicoli
    Hallam, Simon
    Oakervee, Heather
    Cavenagh, James D.
    BLOOD, 2007, 110 (11) : 796A - 796A
  • [36] Phase I clinical trial of IPI-504, a novel, water-soluble Hsp90 inhibitor, in patients with Relapsed/Refractory multiple myeloma (MM).
    Jagannath, S
    Siegel, D
    Richardson, P
    Mazumder, A
    Sydor, J
    Goddard, J
    Walker, J
    Patterson, J
    Normant, E
    Tong, J
    Palombella, V
    Anderson, K
    Adams, J
    Grayzel, D
    BLOOD, 2005, 106 (11) : 719A - 720A
  • [37] Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial
    Asherie, Nathalie
    Kfir-Erenfeld, Shlomit
    Avni, Batia
    Assayag, Miri
    Dubnikov, Tatyana
    Zalcman, Nomi
    Lebel, Eyal
    Zimran, Eran
    Shaulov, Adir
    Pick, Marjorie
    Cohen, Yael
    Avivi, Irit
    Cohen, Cyrille
    Gatt, Moshe E.
    Grisariu, Sigal
    Stepensky, Polina
    HAEMATOLOGICA, 2023, 108 (07) : 1827 - 1839
  • [38] Safety and clinical activity of ruxolitinib combined with carfilzomib and dexamethasone for patients with carfilzomib-refractory multiple myeloma: results from a phase 1 clinical trial
    Atrash, Shebli
    Symanowski, James
    Norek, Sarah
    Begic, Xhevahire
    Bhutani, Manisha
    Paul, Barry
    Varga, Cindy
    Kin, Andrew
    Jeffrey
    Voorhees, Peter
    Usmani, Saad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S160 - S160
  • [39] Phase I clinical trial of oral administration of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with relapsed/refractory multiple myeloma
    Richardson, P
    Schlossman, RL
    Mitsiades, CS
    Munshi, NC
    Colson, K
    Doss, D
    McKenney, M
    Hande, K
    Gorelik, S
    Lunde, L
    Stepanek, A
    Freeman, A
    Dinand, K
    Hayes, S
    Michelle, R
    Doucet, K
    Warren, D
    Mitsiades, N
    Richon, VM
    Chiao, J
    Anderson, KC
    BLOOD, 2004, 104 (11) : 420A - 420A
  • [40] Update on phase I clinical trial of IPI-504, a novel, water-soluble Hsp90 inhibitor, in patients with relapsed/refractory multiple myeloma (MM).
    Siegel, David
    Jagannath, Sundar
    Mazumder, Amitabha
    Vesole, David
    Borrello, Ivan
    Sydor, Jens
    Wright, Jim
    Patterson, Jon
    Normant, Emmanuel
    Adams, Julian
    Anderson, Kenneth
    Grayzel, David
    Richardson, Paul
    BLOOD, 2006, 108 (11) : 1022A - 1022A
12345